Additional Titles & Roles
- Director, Tobacco Treatment Program, Siteman Cancer Center
Education & Training
- Residency: Washington University, St. Louis, MO, 2004
- ScD: Johns Hopkins University, Baltimore, Maryland, 1998
- MPH: Johns Hopkins University, Baltimore, Maryland, 1995
- MD: National Taiwan University, Taipei, Taiwan, 1993
- Faculty Member, Alpha Omega Alpha (AOA) Honor Medical Society, 2023
- Fellow, Society of Research for Nicotine and Tobacco, 2023
- World Congress of Psychiatric Genetics Travel Award, 2009
- APA Resident Research Award, 2004
- Eli Robins Award, Washington University Department of Psychiatry, 2004
Areas of Clinical Interest
Nicotine Dependence, Schizophrenia, Mood Disorder, Community Psychiatry, Cancer Psychiatry
1. Precision medicine
2. Clinical trials
3. Implementation science
4. Cancer prevention
5. Vulnerable and rural population health
6. Cross-population and public health genomics
- Hohl SD, Matulewicz RS, Salloum RG, Ostroff JS, Baker TB, Schnoll R, Warren G, Bernstein SL, Minion M, Lenhoff K, Dahl N, Juon HS, Tsosie U, Fleisher L, D’Angelo H, Ramsey AT, Ashing KT, Rolland B, Nolan MB, Bird JE, Nguyen CVT, Pauk D, Adsit RT, Tindle HA, Shoenbill K, Yeung S, Presant CA, Wiseman KP, Wen KY, Chichester LA, Chen LS, (2023 May). Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers. J Clin Oncol. 41(15): 2756-2766.
Read publication »Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers.
- Heiden BT, Baker TB, Smock N, Pham G, Chen J, Bierut LJ, Chen LS, (2022 Jul). Assessment of formal tobacco treatment and smoking cessation in dual users of cigarettes and e-cigarettes. Thorax.
Read publication »Assessment of formal tobacco treatment and smoking cessation in dual users of cigarettes and e-cigarettes.
- Chen LS, Hung RJ., Baker TB, Horton A, Culverhouse R, Saccone NL, Cheng I, Deng B, et al, Spitz, MR, Kraft P, Amos CI, Bierut LJ, 2015. CHRNA5 Risk Variant Predicts Delayed Smoking Cessation and Earlier Lung Cancer Diagnosis-A Meta-Analysis. J Natl Cancer Inst. 2015 Apr 14;107(5)
Read publication »CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis–a meta-analysis.
- Chen LS, Baker TB, Miller JP, Bray M, Smock N, Chen J, Stoneking F, Culverhouse RC, Saccone NL, Amos CI, Carney RM, Jorenby DE, Bierut LJ, (2020 Dec). Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther. 108(6): 1315-1325.
Read publication »Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.
- Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, Gogarten SM, Johnson EO, Saccone NL, Wang JC, Weiss RB, Goate AM, Bierut LJ (2012 Jul 1). Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry. 169(7): 735-42.
Read publication »Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.
- Chen LS, Baker, TB, Korpecki, JM, Johnson KE, Hook JP, Brownson RC, Bierut LJ. Low-burden strategies to promote smoking cessation treatment in patients with serious mental illness. Psychiatric Services. 2018 in press.
Read publication »Smoking and genetic risk variation across populations of European, Asian, and African American ancestry–a meta-analysis of chromosome 15q25.
Funded Research Projects
NIDA (MPI): A multilevel intervention to personalize and improve tobacco treatment in primary care
NCI (MPI): Precision prevention strategy to increase uptake and engagement in lung cancer screening and smoking cessation treatment
NCI (Supplement PI): Cancer Center Tobacco Cessation
NCI (Co-I): Integrative Analysis of Lung Cancer Etiology and Risk
NCI (Co-I): Implementation Sciencer Center for Cancer Control
NIDA (Co-I): Mechanisms of Behavior Change in a Genetics-Informed Smoking Cessation Intervention
NIDA (Co-I): Testing the feasibility and acceptability of social media and digital therapeutics to decrease vaping behaviors